Data as of:
LIVE
EXAS
Exact Sciences Corporation · Health Care - Diagnostics
N/A
N/A this month
VERSUS
COMPARE
GDRX
GoodRx Holdings, Inc. · Health Care - Healthcare Technology
$3.38
-4.52% this month
Comparison scoreboard
MIXED SETUPAI Scorei
EXAS N/A
GDRX 23.4
1Y Returni
EXAS N/A
GDRX -20.09%
Fwd P/Ei
EXAS N/A
GDRX 9.92
Target Up.i
EXAS N/A
GDRX +14.02%
Op. Margini
EXAS N/A
GDRX 11.79%
Metrics last refreshed: 9/20/2026
Quick take
EXAS vs GDRX Stock Comparison: AI Score, Valuation, Performance and Upside
EXAS provides cancer screening and diagnostic tests with a growing commercial infrastructure, while GDRX offers a prescription drug price transparency platform with an asset-light business model. Both are healthcare technology companies but serving very different parts of the patient journey.
EXAS vs GDRX compares two health technology companies at different points of their growth trajectories — Exact Sciences' diagnostics-driven cancer screening franchise versus GoodRx's consumer prescription price platform navigating PBM headwinds.
Live analysis · updated 9/20/2026
EXAS and GDRX are closely matched — they split the tracked metrics evenly.
Normalized 1Y performance
EXAS
GDRX
Not enough data to chart yet.
Recent returns
EXAS
GDRX
Analyst price targets & sentiment
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
EXAS
Price target data unavailable
N/A
GDRX
Price target range
analyst mean$4.03
current price$3.38
+14.0% upside to analyst mean
Who should consider this stock?
EXAS may suit investors who:
- Want exposure to the leading non-invasive colorectal cancer screening platform
- Believe Cologuard and next-generation cancer screening tests will continue taking market share
- See the large unscreened colorectal cancer patient population as a long-term growth opportunity
GDRX may suit investors who:
- Want exposure to a consumer healthcare price transparency platform with broad brand recognition
- See value in GoodRx's expansion into telehealth and pharmaceutical manufacturer programs
- Believe GoodRx's core economics will stabilize after recent PBM headwinds
Performance & AI score
| Metric | EXAS | GDRX |
|---|---|---|
| AI scorei | N/A | 23.4 |
| AI ranki | N/A | #3741 |
| Latest closei | N/A | $3.38 |
| 1M returni | N/A | -4.52% |
| 6M returni | N/A | +66.50% |
| 1Y returni | N/A | -20.09% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | EXAS | GDRX |
|---|---|---|
| 1Y ago | N/A | $7.99K (-20.1%) started 2025-09-18 |
| 5Y ago | N/A | $733.98 (-92.7%) started 2021-09-20 |
| 10Y ago | N/A | $669.31 (-93.3%) started 2020-09-23 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | EXAS | GDRX |
|---|---|---|
| Market capi | N/A | $1.21B |
| Trailing P/Ei | N/A | 58.92 |
| Forward P/Ei | N/A | 9.92 |
| Price/Salesi | 6.17 | N/A |
| EV/Revenuei | N/A | 1.81 |
| Analyst targeti | N/A | $4.03 |
| Target upsidei | N/A | +14.02% |
Growth, profitability & risk
| Metric | EXAS | GDRX |
|---|---|---|
| Revenue growthi | N/A | -1.30% |
| Earnings growthi | N/A | -44.50% |
| EPS growthi | N/A | -44.50% |
| FCF margini | N/A | +14.33% |
| Operating margini | N/A | 11.79% |
| Profit margini | N/A | 2.07% |
| ROIC proxyi | N/A | 2.52% |
| Return on equityi | N/A | 2.52% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.66 | 1.58 |
| Debt/equityi | N/A | 83.22 |
| Current ratioi | N/A | 1.38 |
| Quick ratioi | N/A | 0.42 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
EXAS max drawdowniN/A
GDRX max drawdowni62.82%
EXAS max wkly dropiN/A
GDRX max wkly dropi24.29%
5Y risk snapshot
EXAS max drawdowniN/A
GDRX max drawdowni96.03%
EXAS max wkly dropiN/A
GDRX max wkly dropi47.48%
10Y risk snapshot
EXAS max drawdowniN/A
GDRX max drawdowni96.73%
EXAS max wkly dropiN/A
GDRX max wkly dropi47.48%
Performance metrics by period
| Period | Metric | EXAS | GDRX |
|---|---|---|---|
| 1Y | Growthi | N/A | -20.09% |
| CAGRi | N/A | -20.11% | |
| Volatilityi | N/A | 60.70% | |
| Sharpe ratioi | N/A | -0.14 | |
| Sortino ratioi | N/A | -0.21 | |
| Max drawdowni | N/A | 62.82% | |
| Current drawdowni | N/A | 32.80% | |
| Avg drawdowni | N/A | 41.54% | |
| Ulcer Indexi | N/A | 43.76% | |
| Max daily dropi | N/A | 18.78% | |
| Max wkly dropi | N/A | 24.29% | |
| 5Y | Growthi | N/A | -92.66% |
| CAGRi | N/A | -40.73% | |
| Volatilityi | N/A | 72.86% | |
| Sharpe ratioi | N/A | -0.41 | |
| Sortino ratioi | N/A | -0.59 | |
| Max drawdowni | N/A | 96.03% | |
| Current drawdowni | N/A | 92.83% | |
| Avg drawdowni | N/A | 82.23% | |
| Ulcer Indexi | N/A | 84.58% | |
| Max daily dropi | N/A | 38.91% | |
| Max wkly dropi | N/A | 47.48% | |
| 10Y | Growthi | N/A | -93.31% |
| CAGRi | N/A | -36.35% | |
| Volatilityi | N/A | 71.53% | |
| Sharpe ratioi | N/A | -0.34 | |
| Sortino ratioi | N/A | -0.48 | |
| Max drawdowni | N/A | 96.73% | |
| Current drawdowni | N/A | 94.09% | |
| Avg drawdowni | N/A | 75.83% | |
| Ulcer Indexi | N/A | 80.35% | |
| Max daily dropi | N/A | 38.91% | |
| Max wkly dropi | N/A | 47.48% |
Business comparison
| Category | EXAS | GDRX |
|---|---|---|
| Company | Exact Sciences Corporation | GoodRx Holdings, Inc. |
| Sector | Health Care - Diagnostics | Healthcare |
| Industry | N/A | Health Information Services |
| Core business | Exact Sciences provides non-invasive cancer screening and diagnostic tests, led by Cologuard (colorectal cancer screening stool DNA test) and Oncotype DX (tumor profiling tests for breast, colon, and prostate cancer treatment decisions). | GoodRx provides a consumer-facing digital platform for comparing and accessing discounted prescription drug prices across U.S. pharmacies, allowing uninsured and underinsured patients to pay less than list price for their medications. |
| Investor focus | Investors track Cologuard's customer growth and revenue, anticipated next-generation Cologuard screening test launch, and Oncotype DX precision oncology testing volume. | Investors track GoodRx's monthly active consumer growth, prescription revenue (from pharmacy PBM spread), and expansion into newer healthcare services including telehealth and pharmaceutical manufacturer programs. |
EXAS strengths
- Cologuard is the leading non-invasive colorectal cancer screening test with Medicare coverage and broad physician adoption
- Oncotype DX provides genomic test results that guide chemotherapy decisions in breast cancer
- Large addressable market as colorectal cancer screening compliance remains below clinical guidelines
GDRX strengths
- Leading consumer brand for prescription drug price comparison in the U.S.
- Asset-light business model connecting consumers, pharmacies, and pharmacy benefit managers
- Expanding beyond prescription discounts into telehealth and manufacturer direct-to-patient programs
Risks to watch — EXAS
- Cologuard faces competition from Guardant Health's Shield blood-based colorectal cancer screening test
- High operating expenses relative to revenue have kept Exact Sciences unprofitable despite strong Cologuard revenue growth
- Next-generation Cologuard must maintain superiority as competing approaches improve
Risks to watch — GDRX
- Core prescription discount business has faced revenue headwinds from PBM (pharmacy benefit manager) changes affecting discount spread economics
- Growth has moderated significantly from COVID-era highs
- Competition from Amazon Pharmacy, Blink Health, and other prescription discount platforms
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
More comparisons
Browse all 1,000 comparisons